United Therapeutics Corporation

Robbins Arroyo LLP Is Investigating the Officers and Directors of United Therapeutix Corporation (UTHR) on Behalf of Shareholders

Robbins Arroyo LLP is investigating whether certain officers and directors of United Therapeutics Corporation (NasdaqGS: UTHR) breached their fiduciary duties to shareholders. United Therapeutics, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide.

United Therapeutics Reveals Details of Potential Settlement

On July 27, 2017, United Therapeutics disclosed that it set aside $210 million for a possible settlement related to an investigation by the U.S. Department of Justice involving the company’s donations to nonprofit organizations that give patients financial assistance to pay their out-of-pocket drug expenses. The investigation concerns whether these financial contributions violate the Federal Anti-Kickback Statute and the Federal False Claims Act. United Therapeutics further revealed that it is prepared to enter into a corporate-integrity agreement with the federal government that may obligate the company to comply with certain business practices for a number of years.

United Therapeutics Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, or you can complete the form below and we will contact you directly.

 

Shareholder Information

Items marked with an asterisk (*) are required information.

First Name * Last Name *
Phone *
E-mail * Confirm: E-mail *
Number of Shares Owned:
Comments:

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* I have read the disclaimer information
+=

    Send This Post